Transcriptional regulation by C/EBP alpha and -beta in the expression of the gene for the MRP14 myeloid calcium binding protein.
Transcriptional regulation of the gene for the myeloid calcium binding protein, MRP14, was investigated in human monocytic leukemia cell lines. The MRP14 gene was not expressed in monoblastic ML-1 cells, promonocytic U-937 cells, or promyelocytic HL-60 cells. On the other hand, the gene was expressed in monocytic THP-1 cells and in the HL-60 cells treated with 1,25-dihydroxyvitamin D3 (VD3). The level of MRP14 in VD3-treated HL-60 cells was two-fold higher than that in THP-1 cells. Among several known transcription factor binding motifs, nuclear protein(s) of VD3-treated HL-60 cells and THP-1 cells bound to the CCAAT/enhancer binding protein (C/EBP)-binding motif that was located in the upstream region of the MRP14 gene (-81), as evidenced by the competitive gel mobility-shift assay. An antibody for C/EBP alpha super-shifted the nucleoprotein complex in THP-1 cells but not in the VD3-treated HL-60 cells, whereas an antibody for C/EBP beta blocked the formation of the complex with the nuclear factor of the HL-60 cells but not with that of THP-1 cells. An anti-C/EBP delta antibody had no effect on the complex in either cell. Thus, it was concluded that C/EBP alpha and -beta were able to bind to the C/EBP motif, and that C/EBP alpha bound to the motif in THP-1 cells and C/EBP beta bound to that in the VD3-treated HL-60 cells. Furthermore, to examine the transcriptional activity of the C/EBP motif, we transfected several constructed luciferase reporter DNAs into HL-60 cells and THP-1 cells. The luciferase activity of the C/EBP motif in HL-60 cells was increased by VD3 treatment. The C/EBP motif in the MRP14 gene was confirmed to function as a regulatory region in VD3-treated HL-60 cells and THP-1 cells by the assay. Since C/EBP beta was also detected in VD3-untreated HL-60 cells by immunoblotting, VD3 activated C/EBP beta to bind to the motif, probably through post-translational modification.
Kuruto-Niwa
R
R
Laboratory of Microbiology and Host Defenses, University of Shizuoka, Japan. kuruto@fns1.u-shizuoka-ken.ac.jp
Nakamura
M
M
Takeishi
K
K
Nozawa
R
R
D000943:Antigens, Differentiation / Q000096:biosynthesis / Q000187:drug effects / Q000235:genetics* / Q000502:physiology*; D001665:Binding Sites / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D022762:CCAAT-Enhancer-Binding Proteins; D002135:Calcium-Binding Proteins / Q000096:biosynthesis / Q000187:drug effects / Q000235:genetics* / Q000502:physiology*; D040502:Calgranulin B; D002478:Cells, Cultured; D002762:Cholecalciferol / Q000494:pharmacology; D004268:DNA-Binding Proteins / Q000096:biosynthesis / Q000187:drug effects / Q000502:physiology*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000502:physiology*; D018922:HL-60 Cells; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000378:metabolism / Q000473:pathology; D009000:Monocytes / Q000166:cytology; D009687:Nuclear Proteins / Q000096:biosynthesis / Q000187:drug effects / Q000502:physiology*; D011401:Promoter Regions, Genetic / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D014157:Transcription Factors / Q000187:drug effects / Q000502:physiology*; D014407:Tumor Cells, Cultured
D000943:Antigens, Differentiation; D022762:CCAAT-Enhancer-Binding Proteins; D002135:Calcium-Binding Proteins; D040502:Calgranulin B; D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; D014157:Transcription Factors; D002762:Cholecalciferol